The Battle Between MARIPOSA and FLAURA2 Regimens in NSCLC
Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.
How Will ADCs Influence the Treatment Landscape in SCLC?
Experts discussed how treatment should be sequenced for patients with small cell lung cancer who have brain metastases, highlighting recent clinical trial advancements and safety considerations.
How Do Experts Think Dato-DXd Should Be Used in NSCLC?
Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.
The Intricacies of Bispecific Antibodies in Multiple Myeloma
Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.
How Has Teclistamab Administration Translated Into Community MM Settings?
Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.
